Search

Background: In the summer of 2022, the United States faced a nationwide outbreak of mpox, with cases concentrated in sexual and gender minorities who have sex with men. Understanding rates of mpox vaccine uptake and concomitant behavioral change is essential to guide the implementation of targeted public health responses to the potential reemergence of mpox., Methods: Between August 2022 and November 2022, 8551 individuals recruited via geosocial networking apps completed a brief survey that assessed mpox vaccine uptake, intentions to get a mpox vaccine, and behavioral change., Results: In August, 17.4% of participants reported having received at least 1 dose of the mpox vaccine. By November, this prevalence estimate was 35.0%. Black participants were significantly less likely to be vaccinated, and vaccine hesitancy increased among Black participants over time. Among those who had not yet received a vaccination, the intention to get vaccinated decreased over time. We observed trends that coincided with the evolving outbreak, such as decreased worry about mpox and less engagement in risk reduction behaviors over time., Conclusions: Despite a 2-fold increase in mpox vaccine uptake between August 2022 and November 2022 in sexual and gender minorities who have sex with men, disparities in vaccine uptake were observed among Black participants. Findings will guide the implementation of public health responses to the potential reemergence of mpox and other viral infectious diseases (eg, meningitis) with a specific focus on optimizing vaccine uptake in Black communities., Competing Interests: Potential conflicts of interest . A. W. C. reports the following grant or contract: UG3-AI169652 (NIH). C. G. reports the following grants or contracts: R01 AI150502 Rendina/Talan (NIH), UH3 AI 133675 Grov (NIH), UG3-DA058304 Spinelli/Ghandi/Carrico (NIH) and participation on the following data and safety monitoring board or advisory board: UG3AI169658—Schnall/ Garofalo/Duncan (NIH). C. M. reports the following grants or contracts to their institution: 3UH3AI133675-04S1 Nash/Grov MPI (NIH). D. N. reports consulting fees from Gilead and AbbVie. D. A. W. reports NIAAA K01AA029047 (NIH) and NIH Loan Repayment Program L60AA030435 (NIH); grant or department funds received/used for attending meetings and/or travel; and a leadership or fiduciary role on the Student Award Review Subcommittee for the Society for the Scientific Study of Sexuality. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)